Intellia Therapeutics

Cambridge, United States

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

$180.0M raised

Apr 2026

Post-IPO Equity

Biotechnology Genetics Health Care Medical Therapeutics

Top Investors

Novartis OrbiMed Foresite Capital Fidelity EcoR1 Capital

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Intellia Therapeutics

How much funding has Intellia Therapeutics raised?

Intellia Therapeutics has raised $180.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.

Who are Intellia Therapeutics's investors?

Intellia Therapeutics's investors include Novartis, OrbiMed, Foresite Capital, Fidelity, EcoR1 Capital.

Where is Intellia Therapeutics headquartered?

Intellia Therapeutics is headquartered in Cambridge, United States.

What does Intellia Therapeutics do?

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

What stage is Intellia Therapeutics at?

Intellia Therapeutics is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 29, 2026.

MLA

"Intellia Therapeutics — Funding & Investors." VCBacked, April 29, 2026, https://www.vcbacked.co/company/intellia-therapeutics. Accessed July 3, 2026.

APA

VCBacked. (2026). Intellia Therapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/intellia-therapeutics

Wikipedia (cite web)

{{cite web |title=Intellia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/intellia-therapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 29, 2026.